 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...6869707172737475767778...123124» |
- ||| E7386 / Eisai, PRISM Pharma
Enrollment open: KEYNOTE-C83: A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors (clinicaltrials.gov) - Dec 20, 2021
P1b/2, N=108, Recruiting, Sponsor: Eisai Inc.
Not yet recruiting --> Recruiting
- || Clinical, Journal, Checkpoint inhibition: The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. (Pubmed Central) - Dec 18, 2021
Promising antitumor activity was observed for escalation to lenvatinib plus pembrolizumab, entinostat plus pembrolizumab, and relatlimab plus nivolumab. Retreatment, rechallenge and escalation are available options for patients with melanoma who relapse in the adjuvant or advanced setting.
- ||||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Clinical: ENGOT-en9/LEAP-001 is to compare efficacy/safety of 1st-line pembro+lenvatinib vs carbo-taxel in newly dx III/IV or recurrent #endometrialcancer 🔗 https://t.co/RfhtgFZEI5 #PMID: 34799418 @pedroramirezmd @CVulsteke @agz_eriksson @TeamEndo_MSK @IGCSociety @ESGO_society @OncoAlert (Twitter) - Dec 17, 2021
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New trial: Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma. (clinicaltrials.gov) - Dec 16, 2021
P=N/A, N=90, Not yet recruiting, Sponsor: Henan Cancer Hospital
- || lenvatinib / Generic mfg.
Clinical, Journal: Clinical importance of muscle volume in lenvatinib for hepatocellular carcinoma: analysis adjusted with inverse probability weighting. (Pubmed Central) - Dec 16, 2021
Retreatment, rechallenge and escalation are available options for patients with melanoma who relapse in the adjuvant or advanced setting. Pre-sarcopenia was shown to be a significant prognostic factor in patients treated with lenvatinib for u-HCC.
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
Clinical, P2 data, Journal: Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. (Pubmed Central) - Dec 16, 2021
P2
Cabozantinib 60 mg/day has a favorable benefit/risk profile for Japanese patients with advanced HCC who have previously received one or two lines of systemic anticancer therapy including sorafenib. (Clinical trial registration: NCT03586973).
- || lenvatinib / Generic mfg.
Clinical, Journal: Prognostic significance of 8 weeks' relative dose intensity of lenvatinib in treatment of radioiodine-refractory differentiated thyroid cancer patients. (Pubmed Central) - Dec 16, 2021
Multivariate analysis revealed that 8w-RDI at ≥60% was an independent prognostic factor for PFS (HR 0.29; 95% CI 0.09-0.96; p = 0.04). Targeting for ≥60% of the relative dose intensity during the first 8 weeks of lenvatinib treatment can be sufficient to achieve significant tumor shrinkage and prolong PFS in RR-DTC patients.
- | Nexavar (sorafenib) / Bayer, Amgen
Journal: The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. (Pubmed Central) - Dec 16, 2021
In conclusion, robust inhibition of FGF19/FGFR4 is of importance for the exertion of antitumor effects of MKIs. Serum FGF19 levels may function as a predictive marker for drug response and survival in HCC patients treated using sorafenib.
- || lenvatinib / Generic mfg.
Clinical, Journal, Monotherapy, Real-world evidence: Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA. (Pubmed Central) - Dec 16, 2021
At 6 and 12 months, landmark PFS were 85.1 and 64.9%, respectively; landmark OS were 91.8 and 72.6%, respectively. These results affirm the clinical effectiveness of first-line lenvatinib monotherapy in uHCC.
- || Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. (Pubmed Central) - Dec 16, 2021
P3
These results affirm the clinical effectiveness of first-line lenvatinib monotherapy in uHCC. This exploratory analysis of data from REFLECT indicated that body weight-based lenvatinib dosing in patients with uHCC was successful in maintaining efficacy, with comparable rates of TEAEs and dose modifications in the two body weight groups.
- | lenvatinib / Generic mfg.
Journal: ASO Visual Abstract: Prognostic Impact of Surgical Intervention After Lenvatinib Treatment for Advanced Hepatocellular Carcinoma. (Pubmed Central) - Dec 16, 2021
This exploratory analysis of data from REFLECT indicated that body weight-based lenvatinib dosing in patients with uHCC was successful in maintaining efficacy, with comparable rates of TEAEs and dose modifications in the two body weight groups. No abstract available
- || Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Journal: Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. (Pubmed Central) - Dec 16, 2021
In the MSS model, we found that first-line therapy for advanced or recurrent endometrial cancer with P/L increased costs and worsened outcomes compared to C/T. In the MSI-high model, P/L improved survival and QALYs compared to C/T but was not cost-effective at the current cost of the drugs.
- | lenvatinib / Generic mfg.
Journal, Circulating tumor DNA: Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. (Pubmed Central) - Dec 16, 2021
Our study demonstrated that somatic alterations could be detected in the majority of advanced HCC patients by ctDNA profiling and that ctDNA-kinetics during LEN treatment was a useful marker of disease progression. These results suggest that ctDNA profiling is a promising method that provides valuable information in clinical practice.
- || Clinical, Review, Journal: Targeted agents in older patients with gastrointestinal cancers - An overview. (Pubmed Central) - Dec 16, 2021
However, even if most decisions regarding the use of targeted agents in older patients with gastrointestinal cancer remain guided by subanalyses of large trials, data from recent older adult-specific trials are beginning to emerge, particularly in colorectal cancer. This review aims to summarize the existing evidence on treatment of older patients with gastrointestinal carcinomas (colon and rectum, stomach, esophagus, liver, and pancreas) with targeted agents (cetuximab, panitumumab, bevacizumab, ramucirumab, aflibercept, regorafenib, encorafenib, trastuzumab, sorafenib, lenvatinib, cabozantinib, erlotinib, olaparib), and place the evidence in a geriatric oncology perspective.
- || Keytruda (pembrolizumab) / Merck (MSD)
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Efficacy of lenvatinib plus pembrolizumab in hepatocellular carcinoma with metachronous lung metastasis: a report of two cases. (Pubmed Central) - Dec 16, 2021
The two cases showed significant tumor shrinkage and long progression-free survival (>19 months and 12 months, respectively). The findings of the current study and recently published data indicate lung metastasis as a potential clinical therapeutic indicator for efficacy of immunotherapy against HCC.
- | lenvatinib / Generic mfg.
Journal: A rapid, simple and sensitive LC-MS/MS method for lenvatinib quantification in human plasma for therapeutic drug monitoring. (Pubmed Central) - Dec 16, 2021
This method was applied to quantify LENVA in patient's plasma samples and covered the concentration range achievable in patients. In conclusion, a sensitive and robust quantification method was developed and validated to be applied in the clinical setting.
- || Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal: Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: an update. (Pubmed Central) - Dec 16, 2021
Among renal adverse events (RAEs), proteinuria is the most frequently reported in clinical trials and real-life experiences, especially during treatment with lenvatinib or cabozantinib...RAEs should be early recognized and properly managed to avoid renal function worsening and life-threatening consequences. Aiming at providing a comprehensive summary that can help clinicians to identify and manage TKIs-related RAEs in TC patients, we reviewed the current evidence about this topic, from pathogenesis and potential risk factors to diagnosis and treatment.
- || lenvatinib / Generic mfg.
Clinical, P2 data, Journal, PD(L)-1 Biomarker, IO biomarker: Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study. (Pubmed Central) - Dec 14, 2021
Lenvatinib plus PD-1 inhibitors showed promising anti-tumor efficacy in patients with initially unresectable BTC and was generally well tolerated. www.chictr.org.cn, ChiCTR2100044476.
- ||| Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
Review, Journal, Adverse events: Nursing Management and Adverse Events in Thyroid Cancer Treatments with Tyrosine Kinase Inhibitors. A Narrative Review. (Pubmed Central) - Dec 13, 2021
www.chictr.org.cn, ChiCTR2100044476. Early assessment of risk factors and identification of adverse events can help nurses support these patients throughout their clinical-therapeutic pathway, increasing the benefits of treatment and reducing reduction/discontinuation.
- | Ibrance (palbociclib) / Pfizer
Preclinical, Journal: A Patient-Derived Xenograft Model of Dedifferentiated Endometrial Carcinoma: A Proof-of-Concept Study for the Identification of New Molecularly Informed Treatment Approaches. (Pubmed Central) - Dec 13, 2021
Collectively, these data provide proof-of-concept evidence on the value of PDX models for preclinical testing of molecularly informed drug therapy in difficult-to-treat human malignancies. Further clinical research is needed to examine more rigorously the potential usefulness of the lenvatinib and palbociclib combination in patients with DEC.
- | lenvatinib / Generic mfg.
Journal: Association between contrast enhancement on contrast-enhanced CT and lenvatinib effectiveness in hepatocellular carcinoma. (Pubmed Central) - Dec 13, 2021
Therefore, LEN has a strong therapeutic effect on HCC, regardless of the degree of contrast enhancement. Furthermore, AT may prolong the OS of LEN-treated patients with BCLC stage B HCC, regardless of tumour vascularity.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date: Lenvatinib and Pembrolizumab Combination Therapy in HPV-associated Recurrent Respiratory Papillomatosis Patients with Laryngeal, Tracheal, And/or Pulmonary Involvement (clinicaltrials.gov) - Dec 13, 2021
P2, N=21, Not yet recruiting, Sponsor: Massachusetts General Hospital
Furthermore, AT may prolong the OS of LEN-treated patients with BCLC stage B HCC, regardless of tumour vascularity. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: ZSAB-TransGOLP: Tislelizumab?Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer (clinicaltrials.gov) - Dec 13, 2021
P2, N=40, Recruiting, Sponsor: Shanghai Zhongshan Hospital
- Keytruda (pembrolizumab) / Merck (MSD)
Uterine Mesonephric-like Adenocarcinoma: Correlations between Mismatch Repair Protein Expression and Microsatellite Instability and Responses to Lenvatinib Plus Pembrolizumab Combination Therapy (Poster Board Number: 106; LACC West Exhibit Hall A) - Dec 13, 2021 - Abstract #USCAP2022USCAP_1187;
MMR IHC should be carefully interpreted and confirmed with PCR for MSI status. Sustained responses to lenvatinib plus pembrolizumab combination therapy in a subset of uterine MLA cases suggest that dual therapy is a promising treatment of choice for uterine MLA, which is KRAS-mutant and MSS/MMR-proficient.
- | AZD7003 / AstraZeneca
New P1 trial, CAR T-Cell Therapy, Metastases: A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 12, 2021
P1, N=20, Not yet recruiting, Sponsor: Zhejiang University
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer (clinicaltrials.gov) - Dec 10, 2021
P4, N=50, Active, not recruiting, Sponsor: Eisai Pharmaceuticals India Pvt. Ltd
Sustained responses to lenvatinib plus pembrolizumab combination therapy in a subset of uterine MLA cases suggest that dual therapy is a promising treatment of choice for uterine MLA, which is KRAS-mutant and MSS/MMR-proficient. Completed --> Active, not recruiting | Trial completion date: Mar 2021 --> Dec 2022 | Trial primary completion date: Mar 2021 --> Dec 2022
- | lenvatinib / Generic mfg.
Agree with you，maybe Lenvatinib not suitable in LC (Twitter) - Dec 10, 2021
- |||||| Keytruda (pembrolizumab) / Merck (MSD), lenvatinib / Generic mfg.
Clinical: LEAP-007 trial of pembrolizumab + lenvatinib or placebo negative for OS in PD-L1 1% or greater first line metastatic NSCLC. Looking at you TIGIT? 🤞 #lcsm (Twitter) - Dec 9, 2021
- | Opdivo (nivolumab) / Ono Pharma, BMS
Retrospective data, Journal, Checkpoint inhibition: Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study. (Pubmed Central) - Dec 7, 2021
The combination of LEN and ICIs is a promising new strategy for the treatment of HCC patients. However, high-grade hepatic toxicity was observed and further evaluation of this combination is still required.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, IO biomarker, Metastases: A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients (clinicaltrials.gov) - Dec 7, 2021
P2, N=35, Recruiting, Sponsor: Shanghai Chest Hospital
However, high-grade hepatic toxicity was observed and further evaluation of this combination is still required. Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: 475-0708-MT-Lung: Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC (clinicaltrials.gov) - Dec 7, 2021
P2, N=46, Recruiting, Sponsor: Dr Joanne CHIU
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) (clinicaltrials.gov) - Dec 6, 2021
P3, N=434, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma (clinicaltrials.gov) - Dec 6, 2021
P2, N=40, Not yet recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
- | reozalimab (IBI318) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase classification, Trial initiation date: The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC. (clinicaltrials.gov) - Dec 6, 2021
P1, N=30, Recruiting, Sponsor: Hunan Province Tumor Hospital
Recruiting --> Active, not recruiting Phase classification: P2 --> P1 | Initiation date: Mar 2021 --> Aug 2021
- lenvatinib / Generic mfg.
Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: A phase 3, multicenter, randomized controlled trial. (Available On Demand) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_391;
P3
Phase classification: P2 --> P1 | Initiation date: Mar 2021 --> Aug 2021 In conclusion, this trial showed that the combination of lenvatinib plus TACE can improve clinical outcomes and may be the new first-line treatment for patients with advanced hepatocellular carcinoma.
- Nexavar (sorafenib) / Bayer, Amgen
A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC). (In-Person Only | Level 1, West Hall; Poster Board - R6) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_385;
P=N/A
Safety will be collected from initiation of LEN or SOR until the earlier of: 28 days after LEN/SOR discontinuation or the end of observation for patients who did not discontinue. Patients will be followed for survival and subsequent anticancer treatments until the end of observation, irrespective of length of treatment.
- Keytruda (pembrolizumab) / Merck (MSD)
LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC) (In-Person Only | Level 1, West Hall; Poster Board - P1) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_352;
P3
Recruitment began in April 2020, and the planned sample size is 950 patients. The results of the LEAP-012 study will show the clinical benefit of adding lenvatinib plus pembrolizumab to the current standard of care TACE for patients with intermediate-stage HCC not amenable to curative treatment.
- Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen, Tecentriq (atezolizumab) / Roche
IMbrave150: Exploratory efficacy and safety in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab beyond radiological progression until loss of clinical benefit in a global phase III study. (In-Person Only | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_318;
P3
In IMbrave150, pts with maintained clinical benefit continuing atezo after PD may have further benefited from staying on tx, although interpretation is limited by selection bias (prespecified criteria excluding pts with loss of clinical benefit). These data suggest that tx with atezo until loss of clinical benefit may contribute to post-PD outcomes.
- Nexavar (sorafenib) / Bayer, Amgen
Multicenter prospective study to evaluate the efficacy of lenvatinib to achieve conversion surgery for initially unresectable hepatocellular carcinoma: LENS-HCC trial. (In-Person Only | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_307;
The response rate of lenvatinib was similar to that of the REFLECT trial. Postoperative complications directly related to the administration of lenvatinib were not observed, suggesting the safety of preoperative lenvatinib therapy.
- Tyvyt (sintilimab) / Eli Lilly, AiRuiKa (camrelizumab) / Jiangsu Hengrui Medicine
The safety and efficacy of transarterial chemoembolization (TACE) + lenvatinib + programmed cell death protein 1 (PD-1) antibody of advanced unresectable hepatocellular carcinoma. (In-Person Only | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_302;
P1/2
ECOG PS score 0-1; Child-Pugh A/B; BCLC stage B/C.Experience group: TACE + Lenvatinib (12mg when≥ 60kg/8mg when < 60kg QD) + Camrelizumab/ Sintilimab (200 mg ivgtt Q3W);Control group: TACE. TACE + Lenvatinib + PD-1 antibody is safe and effective, and conversion resection after the triple-treatment is feasible for uHCC.
- Tyvyt (sintilimab) / Eli Lilly
Sintilimab plus lenvatinib as conversion therapy in patients with unresectable locally intermediate to advanced hepatocellular carcinoma: A single-arm, single-center, open-label, phase 2 study. (In-Person Only | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_298;
P2
TACE + Lenvatinib + PD-1 antibody is safe and effective, and conversion resection after the triple-treatment is feasible for uHCC. In view of the encouraging response rate observed and the acceptable safety profile, the lenvatinib plus sintilimab regimen may achieve a favorable conversion rate and be a feasible conversion therapy for patients with unresectable locally intermediate to advanced HCC.
- lenvatinib / Generic mfg.
Association of early alpha-fetoprotein response with survival in patients with HBV-related hepatocellular carcinoma receiving lenvatinib. (In-Person Only | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_297;
In view of the encouraging response rate observed and the acceptable safety profile, the lenvatinib plus sintilimab regimen may achieve a favorable conversion rate and be a feasible conversion therapy for patients with unresectable locally intermediate to advanced HCC. AFP is an important prognostic factor and a predictive biomarker of survival benefit for patients with HBV-related uHCC receiving treatment with lenvatinib.
- Avastin (bevacizumab) / Roche
The therapeutic strategy for choosing lenvatinib in systemic therapy for unresectable hepatocellular carcinoma. (In-Person Only | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_296;
LEN is strongly recommended to the patients with ECOG PS0, modified ALBI 1 or 2a, AFP < 400ng/mL, no MVI, and low NLR (< 2.8). When the patients would fulfill all these conditions, the median OS and PFS is over 20 and 12 months, both in patients with and without experience of systemic therapy.
- BI 836880 / Boehringer Ingelheim, ezabenlimab (BI 754091) / Boehringer Ingelheim, Nexavar (sorafenib) / Bayer, Amgen
Phase Ib study of BI 836880 (VEGF/Ang2 inhibitor) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with advanced hepatocellular carcinoma (HCC). (In-Person Only | Level 1, West Hall; Poster Board - C2) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_286;
P1
BI 836880 + ezabenlimab had a manageable safety profile and showed promising activity in pts with untreated and second-line post-sorafenib/lenvatinib advanced HCC. Data continue to mature, particularly in cohort G. Cohort F has been expanded by a further 30 pts.
- Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer, Nexavar (sorafenib) / Bayer, Amgen
Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study. (In-Person Only | Level 1, West Hall; Poster Board - C1) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_285;
P=N/A
REFINE reflects the changing treatment landscape and supports the safety and effectiveness of regorafenib in real-world patients with uHCC who had prior systemic treatment other than sorafenib, including immunotherapy. This interim analysis suggests that patients who received regorafenib in the second line had longer OS than patients who received regorafenib in the third line and beyond.
- Cyramza (ramucirumab) / Eli Lilly, Nexavar (sorafenib) / Bayer, Amgen
Ramucirumab for patients with advanced hepatocellular carcinoma and elevated α-fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2. (In-Person Only | Level 1, West Hall; Poster Board - B9) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_277;
P3
This expansion cohort of REACH-2 represents a non-sorafenib sequencing study in pts with advanced HCC. The safety/efficacy profile of ramucirumab following a non-sorafenib based systemic therapy was consistent with that observed in pts who received prior sorafenib in the Ph3 REACH-2 study.
- Baize'an (tislelizumab) / BeiGene, Novartis, Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208. (In-Person Only | Level 1, West Hall; Poster Board - B7) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_275;
P2
Tislelizumab was investigated beyond the first-line setting, as effective second- and third-line treatment options are limited for pts with advanced HCC and there is an unmet medical need. This analysis indicates that tislelizumab is clinically active and well tolerated in pts with advanced HCC who have received prior systemic treatment with SOR/LEN.
- lenvatinib / Generic mfg.
Transcatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma (TACTICS-L) in Japan: Final analysis. (In-Person Only | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_273;
No new safety signal was observed. Future phase III studies are required to validate this combination therapy.
- Tyvyt (sintilimab) / Eli Lilly
Effectiveness of transarterial chemoembolization combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma. (In-Person Only | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_271;
The TACE procedure was repeated 4-6 weeks later and the chemotherapy regimens used included oxaliplatin (75 mg/m2) and iodized oil mixed with epirubicin (30-50 mg/m2). TACE combined with lenvatinib plus sintilimab is a promising and tolerable therapeutic regimen for patients with unresectable HCC.
- lenvatinib / Generic mfg.
Conversion of initially unresectable hepatocellular carcinoma (HCC) with triple-combination therapy (lenvatinib, anti-PD-1 antibodies, and transarterial therapy): A retrospective analysis. (In-Person Only | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_270;
A triple combination of LEN, anti-PD-1 antibodies and transarterial therapy was well tolerated and effective at converting potentially resectable HCC to resectable disease. These findings warrant confirmation by future prospective studies.